The reduction in the price target by HC Wainwright & Co. could lead to a negative perception among investors, potentially causing a short-term decline in Aadi Bioscience's stock price. However, the maintenance of a Buy rating suggests underlying confidence in the company's fundamentals, which may mitigate some negative impact.